According to Wandong Medical's announcement, net profit attributable to owners of the parent company is estimated to be -101 million yuan to -82.5 million yuan in the first half of 2026, with a profit of 51.3 million yuan in the same period last year, changing from profit to loss; net profit after deducting non-recurring profit and loss is estimated to be -111 million yuan to -93.1 million yuan. The pre-performance loss was mainly due to a decline in gross margin due to “price for volume” collection, increased sales and R&D expenses, and increased exchange losses due to exchange rate fluctuations.

According to Wandong Medical's announcement, net profit attributable to owners of the parent company is estimated to be -101 million yuan to -82.5 million yuan in the first half of 2026, with a profit of 51.3 million yuan in the same period last year, changing from profit to loss; net profit after deducting non-recurring profit and loss is estimated to be -111 million yuan to -93.1 million yuan. The pre-performance loss was mainly due to a decline in gross margin due to “price for volume” collection, increased sales and R&D expenses, and increased exchange losses due to exchange rate fluctuations.